Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
根據國際腎臟學會腎臟健康圖顯示，台灣慢性腎臟病（CKD）盛行率已從2019年的12.2%上升至16.3%。 2024年台灣腎臟學會腎臟病年報指出，年齡標準化透析發生率自2018年以來略有下降，從2019年的每百萬人口309人，下降至2021年的289人，再下降至2022年的290人。儘管年齡標準化透析發生率略有下降，但絕對透析個案數仍持續上升。 2022年末期腎病（ESRD）門急診醫療費用達702.6億元，佔台灣全民健康保險總支出的10.5%，較2021年增加約1%，對醫療體系造成沉重負擔。 自2007年以來，台灣衛生福利部已實施慢性腎臟病（CKD）個案管理計劃，旨在建立高效的共享醫療模式。然而，藥師尚未完全融入這種跨學科方法。鑑於CKD患者通常患有多種合併症和多重用藥，藥師參與團隊醫療在優化藥物治療和預防藥物相關併發症方面可能發揮關鍵作用。To evaluate the effectiveness of pharmacists’ participation in multidisciplinary teams in improving pharmaceutical care outcomes among patients with stage 3–5 CKD.
This observational clinical study included patients with stage 3–5 CKD enrolled between January 2022 and September 2025 at a branch of Taipei City Hospital. Eligible participants had at least two comorbidities, were prescribed more than five medications, and were referred for pharmaceutical care by physicians. Pharmacists conducted comprehensive medication reviews, provided counseling, and offered drug-related consultations. Evaluation indicators included: (1) changes in estimated glomerular filtration rate (eGFR), (2) identification and physician acceptance rate of pharmacist recommendations regarding drug therapy problems, and (3) changes in patients’ medication adherence assessed by the Adherence to Refills and Medications Scale (ARMS).
A total of 159 CKD patients were included: 66 (41.2%) with stage 3, 61 (38.1%) with stage 4, and 32 (20.1%) with stage 5 disease. The mean ARMS score at baseline was 14.94 ± 4.10. After six months of pharmacist-led care, the mean score decreased to 14.72 ± 4.53, and after twelve months to 14.45 ± 4.58, indicating progressive improvement in medication adherence. At baseline, 10% of patients were using nephrotoxic drugs; this proportion declined to 5% after six months and to 0.02% after one year, demonstrating enhanced awareness and avoidance of nephrotoxic medications. Pharmacists identified multiple drug therapy problems, and physician acceptance of recommendations exceeded 85%, suggesting high clinical relevance.
結果表明，藥師參與CKD共享護理有助於提高患者用藥依從性，減少腎毒性藥物暴露，並增強用藥安全性。藥師的積極參與也能促進病患教育，優化藥物治療，並加強跨領域合作。這些發現強調了將藥師納入CKD照護模式的重要性，以改善臨床療效並減輕醫療保健系統的經濟負擔。有必要進行進一步的長期研究，以證實這些益處，並評估其對腎功能進展和醫療保健利用的影響。Pharmacist participation in multidisciplinary CKD care effectively reduces drug-related problems, enhances medication adherence, and improves patients’ drug knowledge and self-management. Incorporating pharmacists into shared-care programs is a feasible and valuable strategy to optimize CKD management in Taiwan.
